Literature DB >> 1328896

Identification of a B2-bradykinin receptor linked to phospholipase C and inhibition of dopamine stimulated cyclic AMP accumulation in the human astrocytoma cell line D384.

A J Balmforth1, F E Parkinson, N Altiok, B B Fredholm.   

Abstract

We have examined the activation of a phospholipase C signal transduction pathway by a B2-bradykinin receptor in the human astrocytoma cell line D384 and how this influences D1-dopamine receptor stimulated cyclic AMP accumulation. Addition of bradykinin to D384 cells resulted in a concentration-dependent (10(-11)-10(-6) M) increase in the accumulation of [3H]inositol phosphates and a similar concentration-dependent transient increase in specific [3H]beta-phorbol-12,13-dibutyrate binding which is indicative of translocation of protein kinase C from the cytosol to the membrane. Changes in intracellular Ca2+ of single cells, measured using the fluorescent indicator dye fura-2, indicated that bradykinin produced a rapid, but transient, increase in intracellular calcium. The Ca2+ response was largely independent of extracellular Ca2+ supporting the idea that receptor activation leads to mobilization of Ca2+ from intracellular stores. However, extracellular Ca2+ was required for a response to a rechallenge with bradykinin. The bradykinin B2-receptor agonist kallidin increased cytosolic Ca2+ in a similar manner to bradykinin. The Ca2+ response to bradykinin could be partially reduced in the presence of the B2-receptor antagonist [D-Arg0-Hyp,D-Phe7,beta-(2-Thienyl)-Ala5,8]-bradykinin, whereas the B1-receptor agonists (Des-Arg9]-bradykinin and [Des-Arg10]-kallidin were ineffective. Bradykinin was also found to attenuate dopamine stimulated cyclic AMP accumulation in D384 cells, at similar concentrations previously observed to stimulate the phospholipase C signal transduction pathway, in the presence of the phosphodiesterase inhibitor, rolipram. In contrast, no attenuation was observed in the presence of the phosphodiesterase inhibitor 1-isobutyl 3-methylxanthine, although the level of dopamine stimulated cyclic AMP observed was lower than in the presence of rolipram.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328896     DOI: 10.1007/bf00173543

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  27 in total

1.  Evidence that muscarinic cholinergic receptors selectively interact with either the cyclic AMP or the inositol phosphate second-messenger response systems.

Authors:  J R Hepler; A R Hughes; T K Harden
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

Review 2.  New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization.

Authors:  D Regoli; N E Rhaleb; S Dion; G Drapeau
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  A radioisotopic method for measuring the formation of adenosine 3',5'-cyclic monophosphate in incubated slices of brain.

Authors:  H Shimizu; J W Daly; C R Creveling
Journal:  J Neurochem       Date:  1969-12       Impact factor: 5.372

4.  Muscarinic cholinergic receptor-mediated activation of phosphodiesterase.

Authors:  R B Meeker; T K Harden
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

5.  Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide.

Authors:  C Boulanger; V B Schini; S Moncada; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

6.  Mechanisms for activation and subsequent removal of cytosolic Ca2+ in bradykinin-stimulated neuronal and glial cell lines.

Authors:  G Reiser; F J Binmöller; F Donié
Journal:  Exp Cell Res       Date:  1990-01       Impact factor: 3.905

7.  Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane.

Authors:  A S Kraft; W B Anderson
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

8.  Bradykinin inhibition of cyclic AMP accumulation in D384 astrocytoma cells. Evidence against a role of cyclic GMP.

Authors:  N Altiok; B B Fredholm
Journal:  Neurochem Int       Date:  1992-09       Impact factor: 3.921

9.  Characterization of dopamine and beta-adrenergic receptors linked to cyclic AMP formation in intact cells of the clone D384 derived from a human astrocytoma.

Authors:  A J Balmforth; K Yasunari; P F Vaughan; S G Ball
Journal:  J Neurochem       Date:  1988-11       Impact factor: 5.372

10.  Role of intracellular calcium mobilization in the regulation of protein kinase C-mediated membrane processes.

Authors:  W S May; N Sahyoun; M Wolf; P Cuatrecasas
Journal:  Nature       Date:  1985 Oct 10-16       Impact factor: 49.962

View more
  7 in total

1.  Bradykinin-induced phosphoinositide hydrolysis and Ca2+ mobilization in canine cultured tracheal epithelial cells.

Authors:  S F Luo; S L Pan; W B Wu; C C Wang; C T Chiu; Y J Tsai; C M Yang
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

2.  Pharmacological and functional characterization of bradykinin receptors in canine cultured tracheal epithelial cells.

Authors:  S F Luo; C T Tsai; W B Wu; S L Pan; Y J Tsai; C M Yang
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells.

Authors:  P Gerwins; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-02       Impact factor: 3.000

4.  Bradykinin and alpha-thrombin increase human umbilical vein endothelial macromolecular permeability by different mechanisms.

Authors:  W D Ehringer; O L Wang; A Haq; F N Miller
Journal:  Inflammation       Date:  2000-04       Impact factor: 4.092

5.  Bradykinin antagonizes the effects of alpha-thrombin.

Authors:  W D Ehringer; M J Edwards; R D Gray; F N Miller
Journal:  Inflammation       Date:  1997-06       Impact factor: 4.092

6.  Ca(2+)-dependent and -independent mechanism of cyclic-AMP reduction: mediation by bradykinin B2 receptors.

Authors:  H Sipma; A den Hertog; A Nelemans
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

Review 7.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.